Nuvation Bio (NUVB) Receivables (2023 - 2026)
Nuvation Bio (NUVB) posted quarterly Receivables of $26.0 million for Q1 2026, up 375.72% year-over-year from $5.5 million in Q1 2025, and up 34.21% quarter-over-quarter from $19.4 million in Q4 2025.
Nuvation Bio (NUVB) Receivables (2023 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Receivables for 4 consecutive years, with $26.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 375.72% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $26.0 million (up 375.72% YoY), while the FY2025 annual figure was $19.4 million, up 18.84% from the prior year.
- Receivables advanced to $26.0 million in Q1 2026 per NUVB's latest filing, from $19.4 million in the prior quarter.
- Across five years, Receivables topped out at $26.0 million in Q1 2026 and bottomed at $3.7 million in Q4 2023.
- Historically, Receivables has averaged $11.1 million across 4 years, with a median of $6.7 million in 2025.
- Annual changes were most pronounced in 2025 — Receivables gained 18.84% — and 2026, when it soared 375.72%.
- Nuvation Bio's Receivables stood at $3.7 million in 2023, then jumped by 340.09% to $16.3 million in 2024, then increased by 18.84% to $19.4 million in 2025, then surged by 34.21% to $26.0 million in 2026.
- Business Quant data shows NUVB's Receivables at $26.0 million in Q1 2026, $19.4 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 31.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.71 Mn |
| Mar 31, 2026 | 25.98 Mn |
| Dec 31, 2025 | 19.36 Mn |
| Sep 30, 2025 | 13.85 Mn |
| Jun 30, 2025 | 6.68 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 16.29 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 4.01 Mn |
| Dec 31, 2023 | 3.70 Mn |